Melanocortin peptide PT 141 is a synthetic melanocortin receptor agonist studied for sexual desire. Learn how it works, dosing, side effects, and safety.
Melanocortin peptide PT 141 (bremelanotide) is a synthetic melanocortin receptor agonist that acts on MC4 receptors in the brain to influence sexual desire. The FDA approved it in 2019 as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD). PT-141 is not approved for men, and it is not an approved treatment for erectile dysfunction in the United States.
What Is Melanocortin Peptide PT 141?
The melanocortin peptide pt-141 began as a side observation in tanning research. Scientists studying melanotan II noticed that participants reported unexpected increases in sexual desire, so they trimmed the molecule down to a shorter, more receptor-selective peptide now called bremelanotide.
PT-141 binds to melanocortin receptors 1, 3, 4, and 5. Its most relevant activity for sexual function is at MC4R, a receptor concentrated in the hypothalamus and other brain regions tied to arousal, motivation, and appetite.
Because it is a peptide, PT-141 is broken down in the body rather than metabolized like a typical oral pill. That is one reason it is delivered by injection instead of by mouth.
How PT-141 Works in the Body
PT-141 is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. It reaches the central nervous system and activates MC4 receptors, which sit on dopamine-related pathways that help regulate sexual motivation.
Unlike PDE5 inhibitors such as sildenafil, PT-141 does not work mainly by increasing blood flow in the penis. Its effects are driven by the brain and nervous system, which is why researchers have studied it in people who do not respond well to standard erectile dysfunction drugs.
Bremelanotide also affects blood pressure through the same receptor family. That effect is central to both its risk profile and the reason one version of the drug was abandoned during development.
PT-141 Peptide Dosage and Forms
The FDA-approved dose of bremelanotide is 1.75 mg injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The label limits use to one dose in 24 hours and no more than eight doses per month.
An earlier intranasal version was studied at doses near 10 mg, but development of the pt-141 peptide nasal spray was discontinued after trials showed rises in blood pressure. That is why the approved product is a prefilled auto-injector rather than a nose spray.
There is no FDA-approved pt-141 peptide dosage for men, because the drug is not cleared for that population. Male studies in the published literature used roughly 1.25 mg to 2 mg subcutaneously, but those are research protocols, not established clinical guidance.
Any pt-141 peptide dosage chart circulating online reflects off-label practice or research conditions rather than an approved schedule. Individual dosing decisions belong with a licensed clinician who can review blood pressure, medications, and cardiovascular history.
| Form | Studied or approved dose | FDA status | Key notes |
|---|---|---|---|
| Subcutaneous injection (Vyleesi) | 1.75 mg, at least 45 minutes before activity | Approved for premenopausal women with HSDD | Capped at 1 dose per 24 hours and 8 doses per month |
| Intranasal spray | About 10 mg in trials | Not approved; development stopped | Blood pressure increases were reported |
| Off-label use in men | 1.25 mg to 2 mg SC in small studies | Not approved | Evidence is limited and results are mixed |
PT-141 for Men: What the Evidence Says
Interest in the pt-141 peptide for men comes mostly from small, older trials rather than a large regulatory program. In an early phase 2 study of men with erectile dysfunction, intranasal bremelanotide improved erections compared with placebo, but the nasal form was later shelved over blood pressure concerns.
Later research that combined bremelanotide with a PDE5 inhibitor produced mixed outcomes. Some men reported better erectile function, while others saw little change, and the studies were too small to settle the question.
No major medical society recommends PT-141 as a first-line treatment for male sexual dysfunction. A prescription written for a woman's HSDD diagnosis is also not the same thing as a male treatment plan, and any use in men is off-label.
Side Effects and Safety Considerations
The most common side effects reported in trials are nausea, flushing, headache, and injection site reactions. Nausea is the side effect most likely to make people stop using the drug.
PT-141 can raise blood pressure for several hours after a dose. The label warns against use in people with uncontrolled hypertension or known cardiovascular disease, and it should not be combined with other medications that increase blood pressure.
A less common but notable effect is darkening of the skin, gums, or nails. This focal hyperpigmentation is linked to melanocortin receptor activity and may fade slowly after the drug is stopped, though in some reports it has persisted.
PT-141 is a prescription medication with real cardiovascular effects, so it should be used under medical supervision rather than self-dosed from online sources.
Research chemical products sold online are frequently mislabeled or impure. PT-141 marketed for research purposes only is not intended for human use and is not verified for sterility or dosing accuracy.
Legal Status and Practical Takeaways
Bremelanotide is a prescription-only medication in the United States, approved in June 2019 for premenopausal women with acquired, generalized HSDD. It is not approved for men, not approved for postmenopausal women on the current label, and not sold over the counter.
- PT-141 is a melanocortin receptor agonist that works mainly through the central nervous system.
- The only FDA-approved form is a 1.75 mg subcutaneous injection for premenopausal women with HSDD.
- The nasal spray version was discontinued during development because of blood pressure increases.
- Evidence in men is limited, mixed, and entirely off-label.
- Common side effects include nausea, flushing, headache, and injection site reactions.
PT-141 is a legitimate prescription drug for one specific diagnosis, but it is not a general-purpose libido booster and it is not approved for men. Anyone with high blood pressure, heart disease, or a history of stroke should speak with a healthcare professional before considering it.
Frequently Asked Questions
Is PT-141 FDA approved for men?
No. Bremelanotide, sold as Vyleesi, is approved only for premenopausal women with hypoactive sexual desire disorder. Use in men is off-label, and the FDA has not reviewed or cleared PT-141 for male sexual dysfunction.
How long does PT-141 take to work and how long do the effects last?
The approved label directs users to inject 1.75 mg at least 45 minutes before anticipated sexual activity. Blood pressure can stay elevated for several hours afterward, and dosing is limited to once every 24 hours.
Can you buy PT-141 peptide nasal spray in the US?
There is no FDA-approved PT-141 nasal spray, because the intranasal version was discontinued during development after blood pressure increases appeared in trials. Powders or sprays sold online as research chemicals are not verified for purity, sterility, or human use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.